Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy.
Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy.
复制标题
DOI：
10.2147/ott.s268309
复制
发表时间：
2021
影响因子：
4
通讯作者：
Saeed A
中科院分区：
文献类型：
--
作者：
Choucair K;Kamran S;Saeed A
肝细胞癌仍然是世界范围内癌症死亡的主要原因之一，因为大多数病例在疾病晚期被诊断出来。Ramucirumab是一种人抗vegfr -2单克隆抗体，已被批准用于先前接受索拉非尼治疗的肝癌患者α-胎蛋白水平≥400 ng/mL的单药治疗。由于大多数患者病情进展，α-胎蛋白水平≥400 ng/mL的患者病情具有侵袭性，预后较差，使得ramucirumab成为该亚组患者的重要治疗选择。这篇文章提供了ramucirumab的临床疗效的全面回顾，并强调了导致其批准的两项主要试验。在讨论与ramucirumab使用相关的某些限制和挑战之前，我们还简要回顾了药物的药理学特性，以及其安全性和毒性概况。最后，我们回顾了已完成和正在进行的临床试验，并重点关注那些涉及基于ramucirumab的联合，即与免疫治疗。
Hepatocellular carcinoma remains one of the leading causes of death from cancer worldwide as most cases are diagnosed at an advanced disease stage. Ramucirumab, a human anti-VEGFR-2 monoclonal antibody, is approved as a monotherapy for the treatment of patients with hepatocellular carcinoma and α-fetoprotein levels ≥400 ng/mL previously treated with sorafenib. As most patients present with an advanced disease, patients with α-fetoprotein levels ≥400 ng/mL have an aggressive disease and a poor prognosis, making ramucirumab an important treatment option for this subgroup of patients. This article provides a comprehensive review of the clinical efficacy of ramucirumab as highlighted in the two major trials that lead to its approval. We also briefly review the agent pharmacologic properties, as well as its safety and toxicity profile, before discussing certain limitations and challenges associated with ramucirumab use. Finally, we review completed and ongoing clinical trials and focus on those involving ramucirumab-based combinations, namely with immune therapy.